Molecular Diagnostics: Making the Right Technology Choice
Client Type: Development-stage diagnostics company
Challenge:
A breakthrough technology promised faster, simpler disease-activity testing but clashed with the firm’s original complex platform. Board, founder, and management were deadlocked over which path to pursue.
Approach:
HBG conducted a full portfolio assessment—market sizing, regulatory timelines, payer and provider adoption potential, and cost comparisons. We interviewed KOLs and board members, synthesized findings, and facilitated a strategy offsite to structure choices and build consensus.
Impact:
The process clarified tradeoffs and enabled board and management agreement on a single technology direction. The company moved forward with a shared vision and implementation roadmap.
Why It Matters:
Scientific innovation can fracture leadership alignment. HBG combines analytic rigor and facilitation skill to help boards make decisive choices.
Thumbnail Summary: HBG helped a diagnostics company navigate board conflict over competing technologies, facilitating data-driven decisions that unified stakeholders and clarified the company’s growth strategy.
SEO Meta Description: HBG helped a diagnostics company align leadership on a single technology path for faster growth.
